Furthermore , this therapy could increase the dem and on radiation re sources .
There is no evidence on which to make a recommendation for patients with node-negative tumours that have not penetrated the muscularis propria .
For patients unable to undergo radiation , adjuvant chemotherapy alone may be of benefit , particularly for those with lymph-node metastases .
There is insufficient evidence from r and omized trials to recommend neoadjuvant chemotherapy , or neoadjuvant or adjuvant radiotherapy or immunotherapy , either alone or in combination , outside a clinical trial .
OBJECTIVE To make recommendations on the use of neoadjuvant or adjuvant therapy in addition to surgery in patients with resectable gastric cancer ( T1 - 4 , N1 - 2 , M0 ) .
OPTIONS Neoadjuvant or adjuvant treatments compared with " curative " surgery alone .
OUTCOMES Overall survival , disease-free survival , and adverse effects .
The radiation fields used can possibly damage the left kidney , result ing in hypertension and other renal problems .
[Cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (II). Cooperative study group on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer supported by the Ministry of Health and Welfare (
A cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer was carried out by Kondo 's group from July 1974 to December 1977 . A total of 848 patients with gastric cancer underwent curative resection were eligible . Of 848 patients , 819 cases with complete description of patient 's background were evaluable : Group A ( surgery + MMC + 5-FU : chemotherapy ) 253 cases , group B ( surgery + MMC + 5-FU + OK-432 or PSK : immunochemotherapy ) 282 and group C ( surgery alone ) 284 . The 5-year corrected survival rates of total cases using Cox 's proportional hazard model were 76.2 % with group A , 73.6 % with group B and 73.3 % with group C. And the 10-year survival rates were 67.6 % with group A , 64.3 % with group B and 63.9 % with group C. The difference in survival rate among groups A , B and C was not statistically significant . In the evaluation of prognostic factors by Cox 's proportional hazard model , level of curative resection , extent of resection , histological stage and Kajitani 's classification had an influence upon survival rates , in which degrees of metastasis in lymph node and serous infiltration were also involved . The significance of postoperative adjuvant immunochemotherapy has not been clarified
Furthermore , this therapy could increase the dem and on radiation re sources .
There is no evidence on which to make a recommendation for patients with node-negative tumours that have not penetrated the muscularis propria .
For patients unable to undergo radiation , adjuvant chemotherapy alone may be of benefit , particularly for those with lymph-node metastases .
There is insufficient evidence from r and omized trials to recommend neoadjuvant chemotherapy , or neoadjuvant or adjuvant radiotherapy or immunotherapy , either alone or in combination , outside a clinical trial .
OBJECTIVE To make recommendations on the use of neoadjuvant or adjuvant therapy in addition to surgery in patients with resectable gastric cancer ( T1 - 4 , N1 - 2 , M0 ) .
OPTIONS Neoadjuvant or adjuvant treatments compared with " curative " surgery alone .
OUTCOMES Overall survival , disease-free survival , and adverse effects .
The radiation fields used can possibly damage the left kidney , result ing in hypertension and other renal problems .